View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. News
  2. Company News
September 11, 2018updated 12 Jul 2022 1:12pm

Cyclacel starts Phase lb/ll trial BRCA mutant breast cancer

Cyclacel Pharmaceuticals has commenced a Phase lb/ll clinical trial to investigate the safety and effectiveness of sapacitabine in combination with olaparib (Lynparza) for the treatment of patients with BRCA mutant breast cancer.

Cyclacel Pharmaceuticals has commenced a Phase lb/ll clinical trial to investigate the safety and effectiveness of sapacitabine in combination with olaparib (Lynparza) for the treatment of patients with BRCA mutant breast cancer.

Free Case Study
img

Direct-to-Patient Trials: How IRT Plays an Important Role in Bellerophon's Direct-to-Patient Trials

As the industry strengthens its focus on patient centricity, Direct-to-Patient clinical trials have emerged as a popular trial design that have the potential to increase patient recruitment and retention. IRT plays a crucial role in the success of a Direct-to-Patient trial. Because drug supplies are being managed and shipped from distribution facilities directly to patients’ homes, a sponsor must have a high-quality system in place to accurately track the chain of custody, ensure patient-blinding and handle other logistical challenges. What You Will Learn Benefits and challenges associated with the Direct-to-Patient model Bellerophon's top considerations when implementing this trial design How IRT can equip study teams to successfully track chain of custody, ensure patient blinding, and handle logistical challenges
by Suvoda
Enter your details here to receive your free Case Study.

The investigator-sponsored, open-label, single-group assignment trial intends to enrol around 64 patients with breast cancer and BRCA1 or BRCA2 mutation.

In the first part of the two-stage trial, Cyclacel will evaluate the safety and tolerability of escalating doses of the study’s drug combination.

The second part of the trial will evaluate the efficacy of the recommended Phase ll dose in 18 patients.

If a pre-specified number of these patients achieve a full or partial response as per RECIST 1.1 criteria, the Phase lb/ll trial will include 28 additional patients.

The Phase lb/ll trial’s primary endpoints include identifying maximum-tolerated dose, recommended Phase ll dose and objective response rate. Its secondary endpoint is progression-free survival.

“The study will help determine if the all-oral combination of sapacitabine and olaparib could provide additional benefit to these patients for whom limited treatment options exist.”

The trial will be held at Dana-Farber Cancer Institute in partnership with Cyclacel and AstraZeneca, which will provide sapacitabine and Lynparza, respectively.

The trial’s principal investigator Sara Tolaney said: “Despite advancements in the treatment of BRCA positive breast cancer, we are continually searching for ways to improve on the standard of care for this disease which carries a poor prognosis for the majority of individuals.

“PARP inhibitor monotherapy is the current standard of care for breast and ovarian cancers with homologous recombination deficient (HRD) cancers, which include those positive for BRCA mutations.

“The study will help determine if the all-oral combination of sapacitabine and olaparib could provide additional benefit to these patients for whom limited treatment options exist.”

BRCA mutation is a change in either of the BRCA1 and BRCA2 genes, which are capable of suppressing tumours.

Related Companies

Free Case Study
img

Direct-to-Patient Trials: How IRT Plays an Important Role in Bellerophon's Direct-to-Patient Trials

As the industry strengthens its focus on patient centricity, Direct-to-Patient clinical trials have emerged as a popular trial design that have the potential to increase patient recruitment and retention. IRT plays a crucial role in the success of a Direct-to-Patient trial. Because drug supplies are being managed and shipped from distribution facilities directly to patients’ homes, a sponsor must have a high-quality system in place to accurately track the chain of custody, ensure patient-blinding and handle other logistical challenges. What You Will Learn Benefits and challenges associated with the Direct-to-Patient model Bellerophon's top considerations when implementing this trial design How IRT can equip study teams to successfully track chain of custody, ensure patient blinding, and handle logistical challenges
by Suvoda
Enter your details here to receive your free Case Study.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Clinical Trials Arena